Investor looking at large stock market screens showing share prices and charts

Cathie Wood Tempus AI Stock Purchase

Cathie Wood has a habit of buying famous AI names when they are having a bad week, and she has just done it again. On Friday, her firm ARK Invest bought 154,521 shares of Tempus AI, a healthcare AI company, in a purchase worth roughly $11.2 million. The stock had fallen about 7% that same day. By the weekend, searches for the trade were trending on Google — because the timing is the story. Tempus reports its quarterly results today, Monday, which makes this a conviction buy placed hours before the numbers land. A related Google world-model launch is covered in Google Genie 4 World Model.

Wood’s trades are watched the way some people watch football transfers. ARK publishes its moves daily, and every purchase gets read as a signal about where smart money thinks AI is going next. This one points at a corner of the industry that gets less attention than chatbots: AI working inside hospitals and cancer labs.

In short: ARK Invest, led by Cathie Wood, bought 154,521 shares of Tempus AI (NASDAQ: TEM) on Friday for about $11.2 million — 93,407 shares through its flagship ARK Innovation ETF (ARKK) and the rest through the ARK Genomic Revolution ETF (ARKG). The buy came on a day when Tempus shares fell 7.22% to $72.22, and just before the company’s earnings report today. In the same round of trading, ARK sold shares of drug maker Eli Lilly. Tempus AI is a precision medicine company that uses AI and one of the world’s largest clinical and molecular data libraries to help doctors personalise treatment, especially in cancer care. This article is general information only, not financial advice.

Investor looking at large stock market screens showing share prices and charts

What ARK actually bought

The details come from ARK’s own daily trade disclosures, which is why the story is solid rather than rumour. The biggest slice — 93,407 shares — went into ARKK, the ARK Innovation ETF, Cathie Wood’s flagship fund and the one most associated with her high-growth bets. The remaining roughly 61,000 shares went into ARKG, the ARK Genomic Revolution ETF, which focuses on gene editing, diagnostics and the technology reshaping medicine. That second detail matters: ARK did not file Tempus under generic tech. It filed it under genomics and the future of healthcare, in two funds at once.

The same disclosure showed ARK selling Eli Lilly stock. Rotating out of a giant, profitable drug maker and into a younger, loss-making AI diagnostics company is a very Cathie Wood trade: sell the safe present, buy the risky future. It is the same instinct that has defined her funds through every nvda stock drop and recovery — volatility, to ARK, is the price of admission rather than a warning sign.

What is Tempus AI

Tempus AI is a Chicago-based healthcare technology company founded and led by Eric Lefkofsky. Its business is precision medicine: matching the treatment to the individual patient using data. The company runs genomic testing — including tissue and blood-based tests used heavily in cancer care — and pairs those results with one of the largest libraries of clinical and molecular data in the world. On top of that data sits AI software that helps physicians choose treatments, match patients to clinical trials, and helps drug companies develop new therapies. Another frontier Google model is covered in Google Gemini 4 Carbon Model.

Its partners and collaborators include some of the biggest names in pharmaceuticals, among them AstraZeneca, GSK, Merck and Bristol Myers Squibb. In other words, Tempus is not selling a chatbot. It is selling the data layer underneath modern medicine, which is about as concrete as ai in medical field applications get. Investors who like the company argue that every test it runs makes its data library — and therefore its AI — harder for competitors to copy.

Scientist in a modern genomics laboratory working with DNA sequencing equipment

Why the timing matters

Buying any stock the Friday before its earnings is a statement. Tempus reports its third-quarter results today, Monday, before the market opens, with a conference call led by Lefkofsky and CFO Jim Rogers. Analysts expect revenue of roughly $410 million, up about 23% from a year earlier, and a small loss of around 9 cents a share. The company has beaten earnings expectations four quarters in a row, and its previous quarter brought in about $382 million, up roughly 22%.

So ARK’s buy says, in effect: we like this company enough to add before a report that could move the stock sharply either way — and we like it more at $72 after a 7% fall than we did at higher prices. Buying into a falling stock just before results is either confidence or recklessness, and which word applies will be decided by today’s numbers. If revenue and guidance impress, Friday’s purchase looks timed to the hour. If the report disappoints, ARK will own more of a falling stock, and the trade will be quoted back at Wood for months.

The other side of the story

A balanced read has to include the awkward detail: while ARK was buying, Tempus insiders were selling. Executives at the company sold a combined sum reported at around $59.7 million of stock over the past ninety days, with no insider purchases in the same period. Insider selling has many innocent explanations — tax, diversification, pre-set trading plans — but the contrast is hard to unsee. The most famous outside investor is buying the dip while the people running the company have been reducing their exposure ahead of the same earnings report.

There are broader questions too. Tempus is still loss-making while it builds scale, and AI healthcare stocks carry the same valuation debate as the rest of the sector — the one at the heart of the what is ai bubble argument. Bulls see a data moat and a huge market. Bears see a diagnostics company priced like a software rocket ship. Both can point at today’s earnings for evidence, which is exactly why the stock is likely to move.

What happens next

Everything now hangs on today’s report and, even more, on the guidance that comes with it. Watch three things: whether revenue lands near that $410 million expectation, whether losses keep narrowing at the pace the last four beats suggested, and whether management talks up its data and AI deals with big pharmaceutical partners. Then watch ARK’s next few daily disclosures. If the stock jumps and ARK buys more, the conviction story strengthens. If it falls and ARK quietly stops, Friday’s trade becomes a footnote.

Whatever happens, the purchase has already done one thing: it put a healthcare AI company at the centre of the market’s weekend conversation, ahead of bigger and louder names. That is the Cathie Wood effect — and for Tempus AI, today is the day the spotlight gets its answer. A contrasting platform policy for games is covered in Valve Steam AI Games Cloning Policy.

Doctor in a modern hospital using a tablet with medical data and AI software

Frequently asked questions

What did Cathie Wood buy in Tempus AI?

ARK Invest bought 154,521 shares of Tempus AI on Friday, worth about $11.2 million. Most of the purchase — 93,407 shares — went into the ARK Innovation ETF (ARKK), and the rest went into the ARK Genomic Revolution ETF (ARKG). The trades were published in ARK’s daily disclosure, which is how the purchase became public.

What does Tempus AI do?

Tempus AI is a precision medicine company. It runs genomic tests, mainly for cancer care, and combines the results with one of the world’s largest libraries of clinical and molecular data. Its AI software helps doctors personalise treatment, match patients with clinical trials, and helps drug companies develop new therapies.

Why did ARK buy Tempus AI stock before earnings?

The purchase looks like a conviction buy into weakness. Tempus shares fell about 7.22% to $72.22 on the day of the purchase, and the company reports earnings today. Buying just before results, at a lower price, suggests ARK expects the report and the company’s growth story to hold up — though only today’s numbers will confirm whether the timing was right.

When does Tempus AI report earnings?

Tempus reports its third-quarter results today, Monday, before the US market opens, followed by a conference call at 8:45 a.m. Eastern Time led by founder and CEO Eric Lefkofsky and CFO Jim Rogers. Analysts expect revenue of roughly $410 million and a loss of about 9 cents per share.

Did ARK sell anything in the same round of trades?

Yes. The same disclosures showed ARK selling shares of Eli Lilly, the large pharmaceutical company. The pairing fits Cathie Wood’s long-running style — rotating out of a mature, profitable drug maker and into a younger, faster-growing AI company in healthcare.

Should I buy Tempus AI stock after Cathie Wood’s purchase?

This article cannot answer that — it is general information, not financial advice. A famous investor’s purchase is a signal worth noticing, not a guarantee: Tempus is still loss-making, its insiders have been selling, and its earnings today could move the stock sharply in either direction. Any decision depends on your own finances and risk tolerance.

Leave a Reply

Your email address will not be published. Required fields are marked *